
How 'Direct Primary Care' Works For Patients, Providers, And Payers
getty
In my endless quest for delivery models that provide patients with easy access to high-quality and affordable primary care, I am driving through the Austin, TX suburb of Leander looking for a clinic operated by Frontier Direct Care.
The first thing I notice is that it's very hard to find. Waze directs me to its address in a small strip center, but my destination appears to be occupied by a bar & grill. I nervously call Frontier's founder and CEO, Bibb Beale, who has agreed to meet me there and show me around. Fortunately, he picks up and assures me that the clinic is there, just behind the bar & grill. Checking again, I find the inconspicuous clinic, which has no external signage. It says 'Frontier Direct Care' in small letters on one of the double-entry doors and 'Leander ISD' on the other.
The second remarkable thing I notice, walking in, is that there is no receptionist and no patients in the attractive but very quiet waiting room. Bibb explains that the reason for this is that the clinic is entirely dedicated to Leander Independent School District (ISD) employees (thus there is no need for it to be in a more visible retail location), and that approximately 13% of the 6,400 employees covered by their health plans have opted for this health benefit thus far—even though the clinic only opened a few months ago.
Beale says that the clinic has eight physicians and advanced practice providers, so each provider would have a maximum of 800 patients in their panel (about 100 today) if all of Leander ISD's covered employees enrolled. Compare this to 1,500-2,500 patients in most traditional primary care practice panels. Frontier patients make in-person appointments online (they also initiate virtual appointments), and their dedicated provider meets them when they arrive, so no receptionist is required.
'How is it possible to provide this level of white glove care?' I ask. He tells me that it is because they don't take insurance or the related cost of processing claims, which are estimated to consume 10-15% of all healthcare-related expenses. Instead, they contract directly with Leander ISD (and other employers, and in other markets), which pays them a monthly per-employee fee to provide essentially unlimited primary care services to their employees who don't have to worry about deductibles, co-pays, coinsurance, and other out-of-pocket costs.
The result is that patient satisfaction is very high (94 Net Promoter Score); providers like it because they have small patient panels, can spend more time with their patients, and don't have to spend any time on insurance-related administrative tasks (making it easy to recruit and retain, which is a huge benefit given widespread healthcare staffing challenges); and Leander ISD likes it because they have satisfied employees who are getting better and less expensive healthcare.
This is the still-young but rapidly growing Direct Primary Care (DPC) model. It is different from also fast-growing 'Concierge' practices, in which providers shrink their patient panels and charge annual fees for preferential access but still largely depend on insurance reimbursements.
The number of DPC practices has grown from about 500 in 2015 to more than 1,400 today, and annual membership growth—including both individual and employer-sponsored memberships—is estimated to be 30-40%.
According to a 2024 study by the American Academy of Family Physicians (AAFP), about 9% of their members are practicing in a DPC today. 84 percent of DPC practices don't accept any form of insurance; monthly membership fees average $50-$100 for individuals and $100 or more for families; and two-thirds of DPC practices participate in employer-based contracts (while Frontier's Leander clinic is dedicated to a single client, they and other DPC providers frequently have multiple clients' employees sharing a clinic).
98 percent of the AAFP study physician respondents said they felt that the quality of care provided to patients was better in a DPC clinic than in conventional practices, and overwhelming numbers of the respondents felt that practicing in a DPC clinic improved professional and personal satisfaction (97%), their ability to practice medicine (94%), and their patient relationships (94%).
The value proposition for employees, patients, and providers is not hard to understand, but how does DPC save money for employers in an era when employee benefit costs have been rising at a 5-6% rate and frequently are the fastest-growing line items in employer budgets?
First, because DPC provides comprehensive primary care (the absence of which has been shown to be a key driver of healthcare costs) with a focus on preventive care, which frequently is not a priority for providers who accept insurance because insurance generally does not reimburse adequately for it. In any case, many providers don't have time to deliver preventive care because they are running so hard with large patient panels to maximize visit volume in order to be financially viable.
In addition, since patients being treated in DPC practices don't have to worry about deductibles, co-pays, and coinsurance, they are less likely to delay or skip important visits related to chronic conditions and other health issues that can turn into serious and expensive medical problems if not caught early and managed effectively. Research also shows that DPC patients are less likely to use more expensive forms of care, including ERs and specialists.
Furthermore, the healthier employees that DPC enables through regular care from a dedicated and unhurried provider are more likely to be productive (increased presenteeism) and less likely to skip work (reduced absenteeism). Their ability to make appointments with little or no waiting increases productivity by reducing time away from worksites. Finally, offering DPC can be a differentiator in a tight labor market, and satisfied employees are less likely to leave their employers, reducing costly turnover.
Employees who elect DPC for their primary care frequently couple it with High-Deductible Health Plans and other forms of insurance, so they are covered in case they need more complex care and/or high-cost drugs. However, some DPC providers—including Frontier—also help patients and their employers in these areas .
Many DPC providers negotiate directly with prescription drug manufacturers and wholesalers, or work with Amazon Pharmacy, Good Rx, and other third parties to give their patients access to generic and other common medications at prices that are significantly less than what they would pay at retail pharmacies. Generic antibiotics and steroids, for example, sometimes cost DPC patients $5.00, or even less, and are dispensed at their clinics or shipped directly to their homes. DPC providers also negotiate discounted rates with local pharmacies, labs, and imaging centers as part of bundled service agreements.
In addition, Frontier and other DPC providers also negotiate cash discounts for high-cost specialty drugs, specialist care, and hospital-based acute care. If these prices are less than what their employer clients would otherwise expect to pay through a Pharmacy Benefit Manager (PBM) or insurance company-operated Third-Party Administrator (TPA), clients reimburse their DPC partners outside of monthly fee arrangements, including small mark-ups. This is yet another way DPC providers help employers save money while providing access to high-quality care for their employees.
It was hard to find Frontier's Direct Primary Care clinic, but I'm glad I did. No single healthcare delivery model works for everyone, but increasing access to primary care is critical to improving population health and reducing costs, and it's hard to find models that work for patients, providers, and payers. Direct Primary Care qualifies in this regard, and it deserves an increasingly prominent role in our nation's healthcare delivery system.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
10-07-2025
- Business Wire
Sanger Sequencing of Borrelia burgdorferi flaB Gene Paralogs Can Detect a Single Bacterium for the Diagnosis of Lyme Disease Spirochetemia, Reported Milford Molecular Diagnostics Laboratory
MILFORD, Conn.--(BUSINESS WIRE)--Sin Hang Lee, M.D., director of Milford Molecular Diagnostics Laboratory in Milford, Conn., announces that the Borrelia burgdorferi spirochetes invading the blood stream of the patients at the early localized stage of Lyme disease have duplicate flaB gene paralogs in their chromosome. For Sanger sequencing-based diagnosis of Lyme disease spirochetemia, the flaB gene with its paralogs is a more sensitive chromosomal target than the 16S rRNA gene aiming to detect a single Borrelia burgdorferi bacterium in venous blood specimens, as reported in an article published in Frontier in Bioscience-Scholar The article emphasizes the importance of timely differential centrifugation of the whole blood specimens to isolate the platelet fraction, which contains the spirochetes, for DNA extraction because delayed centrifugation allows the highly mobile spirochetes to attach to and invade the lymphocytes in the test tube at ambient temperature, then to be lost in the buffy coat. These findings are based on a study of the platelet-rich plasma specimens from 145 people, including 98 symptomatic patients, residing in Lyme disease-endemic areas in the United States during a Lyme disease season in 2023. Based on the findings of this study, Dr. Lee has sent an open letter to the director of the Centers for Disease Control and Prevention urging the CDC to assist the hospital laboratories located in Lyme-disease endemic areas to implement methods to detect spirochetemia for early diagnosis and timely treatment of Borrelia burgdorferi infections Milford Molecular Diagnostics Laboratory is CLIA-certified. Its 'nested PCR and direct automated DNA sequencing-based method for qualitative detection/identification of Borrelia burgdorferi (Lyme disease) and Borrelia miyamotoi in whole blood specimens' is also approved by the New York State Department of Health for residents of the State of New York, said Dr. Lee. Healthcare providers and laboratories interested in DNA sequencing-based diagnosis of Lyme disease spirochetemia for their patients may obtain more information by contacting Milford Molecular Diagnostics Laboratory via


Business Upturn
22-06-2025
- Business Upturn
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
By GlobeNewswire Published on June 23, 2025, 00:35 IST New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors 1 . . Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk 1 . . FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system 2 . . These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3. Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. In the study, the first Mim8 maintenance dose was administered on the next planned emicizumab dosing day. Patients were given the option of switching to once-monthly, once every two weeks or once-weekly dosing frequencies of Mim8, regardless of their prior dosing frequency1,3. Steady-state Mim8 concentration was achieved by Week 16, and emicizumab elimination was completed by Week 261. Switching to Mim8 led to a sustained increase in thrombin peak levels without an exaggerated thrombin response1. 'Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with haemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period,' said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. 'This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease.' The open-label phase 3b FRONTIER5 study consisted of 61 adults and adolescents, aged 12 years and older, with haemophilia A. Mim8 was well-tolerated with no safety concerns. No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no clinical evidence of neutralising anti-Mim8 antibodies1. The PROs data from FRONTIER5 indicated a strong overall preference for the Mim8 pen-injector, with 97% (n=57/59) of patients reporting a 'very strong' or 'fairly strong' preference in comparison to their previous emicizumab injection system2. Of the participants who completed the Haemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector 'very easy' or 'easy' to use, and 95% (n=56/59) found it 'much easier' or 'easier' compared with their previous administration method. All participants (100%) were 'extremely confident' or 'very confident' in using the pen-injector correctly, and most participants (83%; n=49/59) found it 'very easy' to inject the dose2. 'The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with haemophilia A and demonstrate our continued commitment to developing innovative treatment options for this community', said Stephanie Seremetis, chief medical officer and CVP for Haemophilia at Novo Nordisk. 'These results give valuable insights into haemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device.' Novo Nordisk expects to submit Mim8 for regulatory review during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026. About haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding4. It is estimated to affect approximately 1,125,000 people worldwide5. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing4. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX4. Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe haemophilia A develop inhibitors6 that can cause replacement therapies to stop working. About Mim8 Mim8 is an investigational FVIIIa mimetic bispecific antibody optimised with the aim to deliver improved potency and sustained efficacy across flexible dosing intervals up to once-monthly prophylaxis for people living with haemophilia A, with or without inhibitors7-10. Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity into the normal range, helping blood to clot7,11. The use of Mim8 in people living with haemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trial FRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with haemophilia A, with or without inhibitors3. The FRONTIER clinical programme investigates Mim8 as a prophylaxis treatment for people with haemophilia A, with or without inhibitors. This programme includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER53,12-15. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Available at: Last accessed: June 2025. MedlinePlus. Hemophilia. Available at: Last accessed: June 2025. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. doi: 10.5045/br.2019.54.3.204. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. doi: 10.1182/blood.2020010331. Mancuso EM, et al. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study. Abstract presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress. Kenet G, et al. Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: phase 3 FRONTIER3 study. Abstract presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2025 Annual Congress. Session 6. Chowdary P, Banchev AM, Kavakli K, et al. Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study. Abstract presented at the American Society of Hematology (ASH) 2024 Annual Congress. Session: 322. U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Available at Last accessed: June 2025. A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1). Available at: Last accessed: June 2025. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Available at: Last accessed: June 2025. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.


New York Post
19-06-2025
- New York Post
Jenna Bush Hager reveals topless sunbathing once left her chest green — dermatologist reveals why
Here's another reason to slather on some SPF this summer — especially if you're planning to bare it all. Jenna Bush Hager revealed this week that a trip to a topless beach in Spain during high school left her so scorched, her chest turned green. 'If you get burned, it's not pretty,' the 43-year-old 'Today With Jenna & Friends' co-host told actress Leslie Bibb on Tuesday's episode. 5 Actress Leslie Bibb appeared on the June 16 episode of 'Today With Jenna & Friends.' NBC When Bibb, 51, asked if her chest peeled, Bush Hager nodded — but then took things in a bizarre turn. 'They may have turned green,' the TV personality said. 'The opposite of the color wheel!' 'They turned green? Are you for real life?' the White Lotus star gasped. 'Oh, I don't think that's good,' Bibb added — and she's probably right. Sunburns happen when you're exposed to too much ultraviolet (UV) light, which can penetrate into deep layers of the skin and cause cellular damage, according to the Mayo Clinic. The body responds by increasing blood flow to the area, leading to inflamed skin we know as a burn. 'Signs that your burns are significant include painful redness, peeling and blisters,' Dr. Lauren Taglia, a dermatologist, told Northwestern Medicine. In Bush Hager's case, her Elphaba-esque chest may have signaled something more serious going on beneath the surface. 5 Bush Hager's chest 'turned green' after a bad sunburn. NBC 5 'Green!' Bibb exclaimed. 'That… makes me sick.' TODAY with Jenna & Friends / TikTok 'When the skin barrier is significantly damaged from a bad sunburn, it's possible to develop a secondary bacterial infection,' Dr. Adarsh Vijay Mudgil, medical director of Mudgil Dermatology, told The Post. Mudgil hasn't treated Bush Hager personally, but he speculated that her symptoms could be caused by impetigo, a common and contagious bacterial skin infection. 'This can lead to the formation of yellowish-green crusts, which would explain the green color she described,' Mudgil explained. 'Impetigo can be painful and requires antibiotics for treatment, either topical or systemic, depending on how widespread the infection is,' he noted. Gross? Bush Hager agrees. 5 All skin types can burn, though those with a lighter complexion are more at risk. Evgen – The former first daughter said the experience was enough to scare her away from sunbathing for good. 'I try not, but this is years of sun damage,' she admitted, rubbing her arms and adding that she now gets regular skin checks. She also offered some sage advice for viewers: wear sunscreen, especially when you're young. 'SPF babies, SPF! Get hip with it!' Bibb chimed in. Dermatologists agree. For daily use, most experts recommend using sunscreen with an SPF of at least 30. If you're spending extended time outdoors, SPF 60 or higher is smart, according to Johns Hopkins Medicine. For full-body coverage, aim for about one ounce of sunscreen — roughly a shot glass. And don't forget to reapply every two hours, or more if you're swimming or sweating. Even if you're inside, you're not off the hook. 5 Hager Bush, a mom-of-three, wishes her younger self hadn't tanned so much. Instagram/jennabhager 'Most ultraviolet (UV) rays can penetrate glass, so if you're working or relaxing near a window, you're receiving sun exposure,' Dr. Elisabeth G. Richard, a dermatologist, told the Skin Cancer Foundation. The bright side: you won't have to reapply as frequently as you would outdoors, likely every four to six hours. 'Sun damage is cumulative,' Richard noted. 'So even if you're only exposed for a short time, it's important to have protection.' Experts also recommend doubling up with wide-brimmed hats, sunglasses and protective clothing for extra coverage. When the sun's at its peak — between 10 a.m. and 2 p.m. — your best bet is to head for the shade. And if a green chest isn't warning enough, don't forget: Every sunburn — even a mild one — increases your risk of skin cancer, including melanoma, the deadliest form of all. In fact, just one blistering burn in childhood or adolescence more than doubles your risk of melanoma later in life, according to the Skin Cancer Foundation. The American Cancer Society estimates that in 2025, 104,960 new melanoma cases will be diagnosed in the US — and 8,430 Americans will die from it.